Novo Nordisk (NVO) has released an update.
Novo Nordisk A/S, a Denmark-based pharmaceutical company, has released updates to its Articles of Association, stating its commitment to financial, environmental, and social responsibility. The share capital stands at DKK 451,000,000, divided into A and B shares, with specific rules regarding the issuance, transferability, and pre-emptive subscription rights. The Board of Directors is authorized to increase share capital by up to DKK 44,650,000 until March 25, 2026, with provisions for both existing shareholders and potential market-priced offerings.
For further insights into NVO stock, check out TipRanks’ Stock Analysis page.
